^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
TQB2868
i
Other names: TQB2868
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Sino Biopharm
Drug class:
PD1 inhibitor, TGFβ inhibitor
Related drugs:
3ms
Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms (clinicaltrials.gov)
P2, N=80, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | N=50 --> 80 | Trial completion date: Oct 2025 --> Nov 2026 | Trial primary completion date: Mar 2025 --> Nov 2026
Enrollment change • Trial completion date • Trial primary completion date
|
gemcitabine • Focus V (anlotinib) • albumin-bound paclitaxel • TQB2868
3ms
Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) (clinicaltrials.gov)
P3, N=566, Not yet recruiting, Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
New P3 trial
|
gemcitabine • paclitaxel • Focus V (anlotinib) • TQB2868
3ms
FASCINATE-N: Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (clinicaltrials.gov)
P2, N=716, Recruiting, Fudan University | Trial completion date: Sep 2025 --> Sep 2028 | Trial primary completion date: Dec 2024 --> Dec 2026
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • FOXC1 (Forkhead Box C1)
|
Herceptin (trastuzumab) • carboplatin • Focus V (anlotinib) • Perjeta (pertuzumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Irene (pyrotinib) • albumin-bound paclitaxel • cyclophosphamide • letrozole • epirubicin • trastuzumab rezetecan (SHR-A1811) • AiRuiYi (fluzoparib) • Andewei (benmelstobart) • AiRuiKang (dalpiciclib) • goserelin acetate • famitinib (SHR 1020) • Yidafan (ivonescimab) • AiRuiLi (adebrelimab) • SHR-4602 • TQB2102 • TQB2868 • anbenitamab repodatecan (JSKN003) • tizetatug rezetecan (SHR-A1921)
11ms
Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms (clinicaltrials.gov)
P2, N=50, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
New P2 trial
|
gemcitabine • Focus V (anlotinib) • albumin-bound paclitaxel • TQB2868
over1year
Efficacy and Safety of HAIC in Combination With TQB2868 and Ramucirumab for Second-line Treatment of Advanced Hepatocellular Carcinoma (clinicaltrials.gov)
P2, N=42, Not yet recruiting, Fudan University
New P2 trial • Combination therapy • Metastases
|
Cyramza (ramucirumab) • oxaliplatin • Tomudex (raltitrexed) • TQB2868
almost2years
A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (clinicaltrials.gov)
P2, N=0, Withdrawn, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Trial completion date • Trial initiation date • Trial primary completion date • Metastases
|
Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • TQB2868
2years
A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (clinicaltrials.gov)
P2, N=0, Withdrawn, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=39 --> 0 | Not yet recruiting --> Withdrawn
Enrollment change • Trial withdrawal • Metastases
|
Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • TQB2868
over2years
A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer (clinicaltrials.gov)
P2, N=39, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
New P2 trial • IO biomarker • Metastases
|
CD8 (cluster of differentiation 8)
|
PD-L1 expression
|
Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • TQB2868
over3years
Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors (clinicaltrials.gov)
P1, N=280, Recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting | Initiation date: Jan 2022 --> Apr 2022
Enrollment open • Trial initiation date • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TGFB1 (Transforming Growth Factor Beta 1)
|
PD-L1 expression
|
TQB2868
almost4years
Clinical Trial of TQB2868 Injection in Subjects With Advanced Malignant Tumors (clinicaltrials.gov)
P1, N=280, Not yet recruiting, Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
New P1 trial • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TGFB1 (Transforming Growth Factor Beta 1)
|
PD-L1 expression
|
TQB2868
Share via
